Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 2021

View Archived Issues

Hanmi initiates phase II study of FLX-475 in combination with pembrolizumab in gastric cancer

Summit selects new preclinical candidate SMT-026738 for CRE infections

Neurocrine initiates phase II trial of NBI-827104 to treat essential tremor

FDA clears IND for Kinnate's RAF inhibitor KIN-2787

First-in-class small molecule PX-69 activates PLXDC2 to treat rheumatoid arthritis

Vaginal HPV16 tumor model created to develop vaccination strategy

Enrollment begins in potentially pivotal study of berubicin in adults with GBM

Roche patents TLR antagonists

ReViral presents new antivirals for RSV

Fujifilm identifies new DHODH inhibitors

Merck & Co. synthesizes new GTPase KRAS mutant inhibitors

Olfactomedin-4 as severity biomarker in bronchiectasis

Checkmate Pharmaceuticals discovers RLR agonists

Study identifies colistin resistance drug target

Keros Therapeutics KER-012 shows promise for the treatment of PAH

Phase II data for peginterferon lambda-1a in uncomplicated COVID-19

China's NMPA approves initiation of phase I/II trial of AK-117 for medium- to high-risk MDS

FDA allows IND for phase I/IIa study of PRL-02 for metastatic prostate cancer

IMB-1018972 is safe and well tolerated in phase I study

First-in-human study begins with MC-I109V for noncirrhotic HBeAg-negative chronic HBV infection

Danish Medical Agency clears initiation of phase IIa study of sepranolone for Tourette's syndrome

CARB-X grant supports Basilea's development of small-molecule inhibitors of DXR

Crescendo Biologics begins phase I study of CB-307 in advanced PSMA-positive solid tumors

PF-07258669 from Sosei and Pfizer collaboration enters clinical trials for anorexia

GammaDelta cleared to conduct phase I study of Vdelta1 gamma-delta T-cell therapy GDX-012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...